Vascular Biogenics Ltd (VBLT)

[staccani]

FDA agreed to not doing a futility/efficacy analysis at this time.
This interim efficacy analysis is irrelevant when we are so close to end of trial. I am very confident that trial will be successful, it is written in the enrollment dates, trial duration and Avastin efficacy.
Then you have the FDA agreeing to skip ph2b and approving directly ph3 in Ovarian Cancer, the opening a a mfg facility in Q4 (before the final rGBM read out) and Lee Trust (an insider) significantly increasing its VBLT holding. It looks like the FDA , VBLT and its main investor are all very confident in VBL111 efficacy and safety. The info I have is enough for me to keep accumulating VBLT before ph3 read out. GLTA